The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.
Aged between 18 - 75 years old
First-time ST-segment elevation myocardial infarction based on the newest ESC guidelines
Timely primary percutaneous coronary intervention within 12 hours from onset
Written informed consent acquired
Known history of or persistent clinical chronic heart failure prior to randomization
Previous use of ARNI, or intolerance or contraindications to study drugs including ARNI or ACEI
History of significant chronic coronary obstruction and adverse ventricular remodeling
History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent or CABG, or planned open-heart surgery within 3 months